Cargando…

The CHEK2 del5395 is a founder mutation without direct effects for cancer risk in the latvian population

Our objective was to determine: 1) whether the checkpoint kinase 2 (CHEK2) del5395 (g.27417113-27422508 del, NC_000022.11) is a founder mutation in the Latvian population, 2) if there is an association between CHEK2 del5395 mutation and cancer risk, and 3) and whether the CHEK2 del5395 mutation impa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Plonis, J, Kalniete, D, Nakazawa-Miklasevica, M, Irmejs, A, Vjaters, E, Gardovskis, J, Miklasevics, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026266/ https://www.ncbi.nlm.nih.gov/pubmed/27785394 http://dx.doi.org/10.1515/bjmg-2015-0083

Ejemplares similares

BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families
por: Berzina, Dace, et al.
Publicado: (2013)

Bladder cancer trends in Latvia during 1990–2017: incidence, mortality, and survival rates
por: Bitiņa-Barlote, Ērika, et al.
Publicado: (2021)

High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients
por: Kalniete, Dagnija, et al.
Publicado: (2015)

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
por: Maksimenko, J., et al.
Publicado: (2018)

Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer
por: MAKSIMENKO, JELENA, et al.
Publicado: (2014)

Von Hippel-Lindau Syndrome: Diagnosis and Management of Hemangioblastoma and Pheochromocytoma
por: Vaganovs, P., et al.
Publicado: (2013)

Allelic variants of breast cancer susceptibility genes PALB2 and RECQL in the Latvian population
por: Hilz, Philip, et al.
Publicado: (2019)

Pathogenic APC Variants in Latvian Familial Adenomatous Polyposis Patients
por: Daneberga, Zanda, et al.
Publicado: (2019)

Chromothripsis and progression-free survival in metastatic colorectal cancer
por: Skuja, Elina, et al.
Publicado: (2017)

Comment on the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology by Lubinski et al., Breast Cancer Res Treat 2008 Apr 15
por: Irmejs, Arvids, et al.
Publicado: (2008)

Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia
por: Plakhins, Grigorijs, et al.
Publicado: (2011)

An Effect of Culture Media on Epithelial Differentiation Markers in Breast Cancer Cell Lines MCF7, MDA-MB-436 and SkBr3
por: Pirsko, Valdis, et al.
Publicado: (2018)

Effectiveness of Secondary Risk–Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study
por: Maksimenko, Jelena, et al.
Publicado: (2022)

Correction: Effectiveness of Secondary Risk–Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study
por: Maksimenko, Jelena, et al.
Publicado: (2023)

Pilot Study on Low Penetrance Breast and Colorectal Cancer Predisposition Markers in Latvia
por: Irmejs, Arvids, et al.
Publicado: (2006)

Pregnancy after breast cancer in BRCA1/2 mutation carriers
por: Maksimenko, Jelena, et al.
Publicado: (2022)

Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review
por: Sæther, Nikolai Havn, et al.
Publicado: (2018)

High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
por: Suspitsin, Evgeny N, et al.
Publicado: (2009)

Challenges in the management of a patient with Cowden syndrome: case report and literature review
por: Melbārde-Gorkuša, Inga, et al.
Publicado: (2012)

BRCA1 mutation in the Triple- Negative Breast Cancer Group
por: Maksimenko, Jelena, et al.
Publicado: (2012)

A novel frequent BRCA1 recurrent variant c.5117G > A (p.Gly1206Glu) identified after 20 years of BRCA1/2 research in the Baltic region: cohort study and literature review
por: Loza, P., et al.
Publicado: (2021)

Clinical, Molecular and Geographical Features of Hereditary Breast/Ovarian Cancer in Latvia
por: Gardovskis, Andris, et al.
Publicado: (2005)

Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers
por: Līcīte, Baiba, et al.
Publicado: (2021)

The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study
por: Alorjani, Mohammed, et al.
Publicado: (2023)

Prevalence of the CHEK2 R95* germline mutation
por: Knappskog, Stian, et al.
Publicado: (2016)

Population Screening of CHEK2 Mutations in Poland
por: Cybulski, Cezary, et al.
Publicado: (2006)

CHEK2 mutations in pediatric brain tumors
por: Tlais, Dana, et al.
Publicado: (2023)

The Latvian language in the digital age
por: Rehm, Georg, et al.
Publicado: (2012)

Genomic profiling of CHEK2*1100delC-mutated breast carcinomas
por: Massink, Maarten P. G., et al.
Publicado: (2015)

Detection of Allelic Variants of The POLE and POLD1 Genes in Colorectal Cancer Patients
por: Pätzold, LA, et al.
Publicado: (2017)

CHEK2 (∗)1100delC Mutation and Risk of Prostate Cancer
por: Hale, Victoria, et al.
Publicado: (2014)

Platinum-Based Chemotherapy Secures Effective Local Control for Very Advanced Hereditary Triple-Negative Breast Cancer with Life-Threatening Bleeding
por: Irmejs, Arvids, et al.
Publicado: (2017)

The CHEK 2 GENE mutations and the risk of Gastric cancer
por: Teodorczyk, Urszula, et al.
Publicado: (2012)

Selenium and cancer risk in CHEK2 mutation carriers
por: Gupta, Satish, et al.
Publicado: (2012)

Current perspectives on CHEK2 mutations in breast cancer
por: Apostolou, Panagiotis, et al.
Publicado: (2017)

Impact of orphan drugs on Latvian budget
por: Logviss, Konstantins, et al.
Publicado: (2016)

Survival of bladder or renal cancer in patients with CHEK2 mutations
por: Złowocka-Perłowska, Elżbieta, et al.
Publicado: (2021)

CHEK2 1100 delC mutation in Russian ovarian cancer patients
por: Krylova, Nadezhda Yu, et al.
Publicado: (2007)

Point mutations associated with Leber hereditary optic neuropathy in a Latvian population
por: Aitullina, Aleksandra, et al.
Publicado: (2013)

A Case of Male Breast Cancer Patient with CHEK2*1100delC Mutation
por: Nguyen, Quan D, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mmdcpodogl4uof11940qhn9eqr